Cd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Hepatic adeno-associated virus (AAV)-serotype 2 mediated gene transfer results in transgene product expression that is sustained in experimental animals but not in human subjects. We hypothesize that this is caused by rejection of transduced hepatocytes by AAV capsid-specific memory CD8(+) T cells reactivated by AAV vectors. Here we show that healthy subjects carry AAV capsid-specific CD8(+) T cells and that AAV-mediated gene transfer results in their expansion. No such expansion occurs in mice after AAV-mediated gene transfer. In addition, we show that AAV-2 induced human T cells proliferate upon exposure to alternate AAV serotypes, indicating that other serotypes are unlikely to evade capsid-specific immune responses.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Detection of AAV components by the innate immune system also leads to the AAV-directed adaptive immune response and potential loss of transgene expression in transduced cells (Mingozzi et al., 2007; Xiang et al., 2020).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Mingozzi et al., 2007
In the citing paper
“Early successes in this field were initially dampened by reports of patients who developed vector insertion-related leukemias directly linked to the viral platform used for transgene delivery11–18.”
From Clonal selection of hematopoietic stem cells after gene therapy for sickle cell disease (2023) · cites this paper as [12]
In the citing paper
“Evidence from early clinical trials, along with subsequent laboratory studies, suggest that CD8+ T cell responses against AAV capsid target transduced hepatocytes (16–18).”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [17]
In the citing paper
“An early clinical trial for the treatment of hemophilia, via i.v. delivery of recombinant AAV (rAAV), resulted in robust CD8 T cell responses and the loss of transgene expression, which was later shown to be mediated by capsid-specific T cell responses.”
From Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells (2021) · cites this paper as [5]
In the citing paper
“Although AAV infection is non-pathogenic in humans, initial exposure induces humoral and cellular anti-capsid response that are reactive to rAAV due to capsid similarity (4, 5).”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [5]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Self-citationMemory CD8+ T cells vary in differentiation phenotype in different persistent virus infections
Appay, V., Dunbar, P. R., Callan, M., Klenerman, P., Gillespie, G. M. A., Papagno, L., Ogg, G. S., King, A., Lechner, F., Spina, C. A., et al. (2002) · Nature Medicine · doi:10.1038/nm0402-379 · Cited by 1,571
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520
Snyder, R. O., Miao, C., Meuse, L., Tubb, J., Donahue, B. A., Lin, H.-F., Stafford, D. W., Patel, S., Thompson, A. R., Nichols, T., et al. (1999) · Nature Medicine · doi:10.1038/4751 · Cited by 409
Mount, J. D., Herzog, R. W., Tillson, D. M., Goodman, S. A., Robinson, N., McCleland, M. L., Bellinger, D., Nichols, T. C., Arruda, V. R., Lothrop, C. D., et al. (2002) · Blood · doi:10.1182/blood.v99.8.2670 · Cited by 339
Self-citationHeparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid
Vandenberghe, L. H., Wang, L., Somanathan, S., Zhi, Y., Figueredo, J., Calcedo, R., Sanmiguel, J., Desai, R. A., Chen, C. S., Johnston, J., et al. (2006) · Nature Medicine · doi:10.1038/nm1445 · Cited by 208
Wang, L., Nichols, T. C., Read, M. S., Bellinger, D. A., & Verma, I. M. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0031 · Cited by 176
Identification of mouse AAV capsid-specific CD8+ T cell epitopes
Sabatino, D. E., Mingozzi, F., Hui, D. J., Chen, H., Colosi, P., Ertl, H. C. J., & High, K. A. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.09.009 · Cited by 91
Self-citation
Research works printed but not linked: 1
- Muzyczka, N. & Berns, K.I. Parvoviridae: The Viruses and Their Replication, 2327–2359 (Lippincott Williams & Wilkins, Philadelphia, 2001).
Cited by
Items 301–400 of 765
Gene therapy for hemophilia – From basic science to first approvals of “one-and-done” therapies
Herzog, R. W., Kaczmarek, R., & High, K. A. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.043 · Cited by 43
“74 77 Multiple capsid T cell epitopes are recognized by humans, and several tend to be conserved across multiple serotypes, making their elimination by capsid engineering a challenge.”
Self-citationAdvances in Cell and Gene-based Therapies for Cystic Fibrosis Lung Disease
Oakland, M., Sinn, P. L., & McCray, P. B. (2012) · Molecular Therapy · doi:10.1038/mt.2012.32 · Cited by 51
Samelson‐Jones, B. J., & Arruda, V. R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00618 · Cited by 43
Gougeon, M.-L., Poirier-Beaudouin, B., Ausseil, J., Zérah, M., Artaud, C., Heard, J.-M., Deiva, K., & Tardieu, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.655478 · Cited by 38
Host and Vector-dependent Effects on the Risk of Germline Transmission of AAV Vectors
Favaro, P., Downey, H. D., Zhou, J. S., Wright, J. F., Hauck, B., Mingozzi, F., High, K. A., & Arruda, V. R. (2009) · Molecular Therapy · doi:10.1038/mt.2009.56 · Cited by 40
Self-citationGene therapy with regulatory T cells: A beneficial alliance
Biswas, M., Kumar, S. R. P., Terhorst, C., & Herzog, R. W. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00554 · Cited by 41
“Anti-capsid effector T cell responses were not predicted by preclinical studies, highlighting one of the major preclinical challenges when working with AAV (34).”
BackgroundInfluentialKhanal, O., Kumar, V., & Jin, M. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.101112 · Cited by 44
Gene therapy in cystic fibrosis
Prickett, M. H., & Jain, M. (2012) · Translational research · doi:10.1016/j.trsl.2012.12.001 · Cited by 46
Targeting adeno-associated virus and adenoviral gene therapy for hepatocellular carcinoma
Wang, Y., Huang, P.-P., Zhang, R., Ma, B.-Y., Zhou, X.-M., & Sun, Y.-F. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i1.326 · Cited by 44
Ertl, H. C. J. (2023) · Drugs · doi:10.1007/s40265-023-01836-1 · Cited by 43
“Adaptive immune responses are mainly directed against the AAV capsid proteins [5], which are not encoded by the vectors’ genome but are provided in trans during vector production.”
BackgroundResultSelf-citationPrevention and Reversal of Antibody Responses Against Factor IX in Gene Therapy for Hemophilia B
Nayak, S., Sarkar, D., Perrin, G. Q., Moghimi, B., Hoffman, B. E., Zhou, S., Byrne, B. J., & Herzog, R. W. (2011) · Frontiers in Microbiology · doi:10.3389/fmicb.2011.00244 · Cited by 40
“Memory CD8+ T cell responses to capsid are also known to occur and may target transduced cells (Manno et al., 2006; Mingozzi et al., 2007b; Li et al., 2011; Mingozzi and High, 2011a).”
BackgroundInfluentialFilling Adeno-Associated Virus Capsids: Estimating Success by Cryo-Electron Microscopy
Subramanian, S., Maurer, A. C., Bator, C. M., Makhov, A. M., Conway, J. F., Turner, K. B., Marden, J. H., Vandenberghe, L. H., & Hafenstein, S. L. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.041 · Cited by 40
Gregorevic, P., Schultz, B. R., Allen, J. M., Halldorson, J. B., Blankinship, M. J., Meznarich, N. A., Kuhr, C. S., Doremus, C., Finn, E., Liggitt, D., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.116 · Cited by 40
MicroRNA silencing and the development of novel therapies for liver disease
Szabó, G., Sarnow, P., & Bala, S. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.01.030 · Cited by 43
“In contrast, the use of AAV2 for in vivo therapy was limited because of early immunologic memory of AAV infections [25].”
The Liver as a Target Organ for Gene Therapy: State of the Art, Challenges, and Future Perspectives
Jacobs, F., Gordts, S. C., Muthuramu, I., & Geest, B. D. (2012) · Pharmaceuticals · doi:10.3390/ph5121372 · Cited by 48
Uncertainty in an era of transformative therapy for haemophilia: Addressing the unknowns
Pierce, G. F. (2020) · Haemophilia · doi:10.1111/hae.14023 · Cited by 39
Self-citationYang, F., Patton, K., Kasprzyk, T., Long, B. R., Gupta, S., Zoog, S. J., Tracy, K., & Vettermann, C. (2021) · Gene Therapy · doi:10.1038/s41434-020-00214-w · Cited by 42
Role of Molecular Genetics in Hemophilia: From Diagnosis to Therapy
Jayandharan, G. R., Srivastava, A., & Srivastava, A. (2012) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0031-1300953 · Cited by 43
Gene therapy for metabolic diseases
Chandler, R. J., & Venditti, C. P. (2016) · Translational Science of Rare Diseases · doi:10.3233/trd-160007 · Cited by 42
“An earlier hemophilia B clinical trial utilized an AAV2 vector, but the transgene expression was transient because of a suspected immune response to the AAV2 capsid, something that might have been predicted given the fact that AAV2 is a common non-pathogenic virus found in humans [65, 66].”
Wu, T.-L., Li, H., Faust, S. M., Chi, E., Zhou, S., Wright, F., High, K. A., & Ertl, H. C. (2014) · Molecular Therapy · doi:10.1038/mt.2013.218 · Cited by 38
Self-citationImmune function in X-linked retinoschisis subjects in an AAV8-RS1 phase I/IIa gene therapy trial
Mishra, A., Vijayasarathy, C., Cukras, C. A., Wiley, H. E., Sen, H. N., Zeng, Y., Wei, L. L., & Sieving, P. A. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.02.013 · Cited by 38
Present and Future of Adeno Associated Virus Based Gene Therapy Approaches
Ortolano, S., Spuch, C., & Navarro, C. (2012) · Recent Patents on Endocrine, Metabolic & Immune Drug Discovery · doi:10.2174/187221412799015245 · Cited by 35
Patton, K. S., Harrison, M. T., Long, B. R., Lau, K., Holcomb, J., Owen, R. E., Kasprzyk, T., Janetzki, S., Zoog, S. J., & Vettermann, C. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.05.012 · Cited by 42
Baruteau, J., Cunningham, S. C., Yılmaz, B. Ş., Perocheau, D. P. B., Eaglestone, S., Burke, D. G., Thrasher, A. J., Waddington, S. N., Lisowski, L., Alexander, I. E., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.09.005 · Cited by 40
“Immune-mediated destruction of transduced hepatocytes is associated with CD8 T cell responses to AAV capsid antigens, which are processed and presented by major histocompatibility complex (MHC) class I.(32) AAV vectors with a single-stranded (ss)DNA genome are able to stimulate the innate immune system through the Tol…”
BackgroundJayandharan, G. R., Zhong, L., Sack, B. K., Rivers, A. E., Li, M., Li, B., Herzog, R. W., & Srivastava, A. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.100 · Cited by 38
“…antibody is proportional to the vector dose administered for AAV1 (Petry et al. , 2008), and the loss of hepatic hF.IX expression in the hemophilia B clinical trial was due to the CD8 þ T cell response to input capsids in patients who received high vector doses (Mingozzi et al. , 2007).”
Translational Data from AAV-Mediated Gene Therapy of Hemophilia B in Dogs
Nichols, T. C., Whitford, M. H., Arruda, V. R., Stedman, H. H., Kay, M. A., & High, K. A. (2014) · Human Gene Therapy Clinical Development · doi:10.1089/hum.2014.153 · Cited by 38
Self-citationAAV-Mediated Gene Delivery to the Liver: Overview of Current Technologies and Methods
Palaschak, B., Herzog, R. W., & Markusic, D. M. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9139-6_20 · Cited by 40
Gene Replacement Therapies for Duchenne Muscular Dystrophy Using Adeno-Associated Viral Vectors
Seto, J. T., Ramos, J. N., Muir, L. A., Chamberlain, J. S., & Odom, G. L. (2012) · Current Gene Therapy · doi:10.2174/156652312800840603 · Cited by 43
Ling, C., Wang, Y., Feng, Y., Zhang, Y., Li, J., Hu, X.-R., Wang, L., Zhong, M., Zhai, X., Zolotukhin, I., et al. (2015) · Journal of Chinese Integrative Medicine · doi:10.1016/s2095-4964(15)60200-x · Cited by 38
Measuring Immune Responses to Recombinant AAV Gene Transfer
Martino, A. T., Herzog, R. W., Anegon, I., & Adjali, O. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-370-7_11 · Cited by 36
Gene therapy for hemophilia: past, present and future
George, L. A., & Fogarty, P. F. (2015) · Seminars in Hematology · doi:10.1053/j.seminhematol.2015.10.002 · Cited by 37
Liver-specific Gene Delivery Using Engineered Virus-Like Particles of Hepatitis E Virus
Lee, E. B., Kim, J., Hur, W., Choi, J. E., Kim, S., Park, D. J., Kang, B.-Y., Lee, G. W., & Yoon, S. K. (2019) · Scientific Reports · doi:10.1038/s41598-019-38533-7 · Cited by 36
Differential T cell immune responses to deamidated adeno-associated virus vector
Bing, S. J., Justesen, S. F. L., Wu, W. W., Sajib, A. M., Warrington, S., Baer, A., Thorgrimsen, S., Shen, R., & Mazor, R. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.01.005 · Cited by 40
“A loss of factor IX transgene expression and transient mild elevations of liver enzymes in circulation were correlated with CD8 T cell responses against the rAAV capsid in the first liver-directed gene therapy trial with rAAV.(7,11) It was later shown that transduced cells present capsid-derived epitopes to cytotoxic…”
BackgroundXiang, Z., Kuranda, K., Quinn, W. J., Chekaoui, A., Ambrose, R., Hasanpourghadi, M., Novikov, M., Newman, D., Cole, C., Zhou, X., et al. (2022) · Human Gene Therapy · doi:10.1089/hum.2021.258 · Cited by 37
“5,6 Furthermore, AAV vector administration commonly triggers immune responses to the capsid antigen 7,8 and potentially the transgene product.”
Self-citationNovel Adeno-associated Viruses Derived From Pig Tissues Transduce Most Major Organs in Mice
Bello, A., Chand, A., Aviles, J., Soule, G., Auricchio, A., & Kobinger, G. (2014) · Scientific Reports · doi:10.1038/srep06644 · Cited by 39
Manufacturing of recombinant adeno-associated viral vectors: new technologies are welcome
Ayuso, E. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2015.49 · Cited by 34
Marcó, S., Haurigot, V., & Bosch, F. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.217 · Cited by 41
Zhan, W., Muhuri, M., Tai, P. W. L., & Gao, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.673699 · Cited by 37
Li, B., Ma, W., Ling, C., Vliet, K. V., Huang, L.-Y., Agbandje‐McKenna, M., Srivastava, A., & Aslanidi, G. (2015) · Human Gene Therapy Methods · doi:10.1089/hgtb.2015.115 · Cited by 35
Wang, Y., Huang, F., Cai, H., Zhong, S., Liu, X., & Tan, W. (2008) · The Journal of Gene Medicine · doi:10.1002/jgm.1177 · Cited by 35
“More recently, the immune responses of the AAV capsids or transgenes products in human clinical studies have been reported [37,38].”
BackgroundOvercoming Immunological Challenges Limiting Capsid-Mediated Gene Therapy With Machine Learning
Wec, A. Z., Lin, K. S., Kwasnieski, J. C., Sinai, S., Gerold, J., & Kelsic, E. D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.674021 · Cited by 36
“Transduced cells process viral capsids through the intracellular proteolytic machinery and present capsid-derived peptides on their surface though the major histocompatibility (MHC) class I molecules (33, 34).”
BackgroundHydrodynamic Delivery: Characteristics, Applications, and Technological Advances
Suda, T., Yokoo, T., Kanefuji, T., Kamimura, K., Zhang, G., & Liu, D. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041111 · Cited by 35
Fang, K., Law, I. K. M., Padua, D. M., Sideri, A., Huang, V., Kevil, C. G., Iliopoulos, D., & Pothoulakis, C. (2017) · American Journal Of Pathology · doi:10.1016/j.ajpath.2017.10.023 · Cited by 36
Obstacles and future of gene therapy for hemophilia
Arruda, V. R., & Samelson-Jones, B. J. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1069179 · Cited by 33
“observed that the majority of human HB subjects (combined 5 of 8) who received the high dose (2 10(12) vg/kg) of AAV2 or AAV8 vector, respectively, for liver-directed FIX gene therapy, develop a CD8 T-cell immune response directed against vector-capsid antigens presented by transduced hepatocytes; if untreated, this c…”
BackgroundOcular Inflammation and Treatment Emergent Adverse Events in Retinal Gene Therapy
Mehta, N., Robbins, D. A., & Yiu, G. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000366 · Cited by 33
Advancements in adeno-associated viral gene therapy approaches: exploring a new horizon
Aalbers, C. J., Tak, P. P., & Vervoordeldonk, M. J. (2011) · F1000 Medicine Reports · doi:10.3410/m3-17 · Cited by 29
Sustained inhibition of hepatitis B virus replication in vivo using RNAi-activating lentiviruses
Ivacik, D., Ely, A., Ferry, N., & Arbuthnot, P. B. (2014) · Gene Therapy · doi:10.1038/gt.2014.94 · Cited by 34
Progress in the molecular biology of inherited bleeding disorders
Pipe, S. W., High, K. A., Ohashi, K., Ural, A. U., & Lillicrap, D. (2008) · Haemophilia · doi:10.1111/j.1365-2516.2008.01718.x · Cited by 33
Self-citationmicroRNAs as therapeutic targets in intestinal diseases
Wang, C., & Chen, J. (2019) · ExRNA · doi:10.1186/s41544-019-0026-9 · Cited by 33
“Nevertheless, miRNA administration based on viral vectors inevitably has security issues, and it is worth considering the accompanying toxicity and immunogenicity when using this delivery system [81].”
BackgroundMary, B., Maurya, S., Kumar, M., Bammidi, S., Kumar, V. S., & Jayandharan, G. R. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00959 · Cited by 34
“8 Thus, a thorough study and modification of the capsid regions that trigger vector recognition and loss of function is likely to improve gene transfer.”
Development of a Clinical Candidate AAV3 Vector for Gene Therapy of Hemophilia B
Brown, H. C., Doering, C. B., Herzog, R. W., Ling, C., Markusic, D. M., Spencer, H. T., Srivastava, A., & Srivastava, A. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.099 · Cited by 34
How not to be seen: immune-evasion strategies in gene therapy
Zaldumbide, A., & Hoeben, R. C. (2007) · Gene Therapy · doi:10.1038/sj.gt.3303082 · Cited by 38
Hepatotoxicity in Adeno-Associated Viral Vector Gene Therapy
Jagadisan, B., & Dhawan, A. (2023) · Current Hepatology Reports · doi:10.1007/s11901-023-00624-5 · Cited by 36
“The T-cell response in humans was initially attributed to an exclusive memory T-cell response in those individuals exposed earlier to AAV [50].”
Update on Progress and Hurdles in Novel Genetic Therapies for Hemophilia
High, K. A. (2007) · Hematology · doi:10.1182/asheducation-2007.1.466 · Cited by 32
“Subsequent mapping of the immunodominant epitope within the AAV capsid, and preparation of a pentamer that recognized the AAV capsid-specific TCR for this patient’s HLA haplotype, allowed direct detection of capsid-specific CD8 T cells, which were shown to proliferate then disappear after vector infusion, with a time…”
BackgroundSelf-citationDavey, M. G., Riley, J. S., Andrews, A., Tyminski, A., Limberis, M., Pogoriler, J. E., Partridge, E., Olive, A., Hedrick, H. L., Flake, A. W., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0171132 · Cited by 30
Hemophilia Gene Therapy: Ready for Prime Time?
VandenDriessche, T., & Chuah, M. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.116 · Cited by 32
“84,85 Although antigen presentation was modest, it may have been suffi-cient to flag the transduced hepatocytes for - cell– mediated destruction.”
Recent Progress in Gene Therapy for Hemophilia
Chuah, M., Nair, N., & VandenDriessche, T. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.088 · Cited by 34
“However, the transduced hepatocytes were able to present AAV capsid-derived antigens in association with MHC class I to T cells (Manno et al. , 2006, Mingozzi et al. , 2007).”
Recombinant adeno-associated Virus: Clinical Application and Development As a gene-therapy Vector
Xiao, P.-J., Lentz, T. B., & Samulski, R. J. (2012) · Therapeutic Delivery · doi:10.4155/tde.12.63 · Cited by 32
Selot, R., Hareendran, S., & Jayandharan, G. (2014) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201015666140327141710 · Cited by 31
“[88] compared the T cell mediated immune response in mice with humans where they analyzed capsid specific CD8+ T cell frequency in immunocompetent mice infused with AAV2 capsid at different doses.”
Fontanellas, A., Hervás-Stubbs, S., Mauleón, I., Dubrot, J., Mancheño, U., Collantes, M., Sampedro, A., Unzu, C., Alfaro, C., Palazón, A., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2009.312 · Cited by 31
Immune responses in liver-directed lentiviral gene therapy
Annoni, A., Goudy, K., Akbarpour, M., Naldini, L., & Roncarolo, M. G. (2013) · Translational research · doi:10.1016/j.trsl.2012.12.018 · Cited by 34
Preclinical and clinical progress in hemophilia gene therapy
Mátrai, J., Chuah, M., & VandenDriessche, T. (2010) · Current Opinion in Hematology · doi:10.1097/moh.0b013e32833cd4bd · Cited by 36
Gene Therapy for Pompe Disease: The Time is now
Colella, P., & Mingozzi, F. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.109 · Cited by 37
Self-citationLiver-Directed Adeno-Associated Viral Gene Therapy for Hemophilia
Markusic, D. M., & Herzog, R. W. (2013) · Journal of Genetic Syndromes & Gene Therapy · doi:10.4172/2157-7412.s1-009 · Cited by 36
“Studies conducted in control human subjects revealed the existence of capsid specific memory CD8 T cells that could be reactivated following exposure to AAV2 and other AAV serotypes, such as AAV8 [65].”
BackgroundPeeling back the layers of immunogenicity in Cas9-based genomic medicine
Stigzelius, V., Cavallo, A. L., Chandode, R. K., & Nitsch, R. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.06.045 · Cited by 33
Adriouch, S., Franck, E., Drouot, L., Bonneau, C., Jolinon, N., Salvetti, A., & Boyer, O. (2011) · Frontiers in Microbiology · doi:10.3389/fmicb.2011.00199 · Cited by 22
“ORIGINAL RESEARCH ARTICLE published: 29 September 2011 doi: 10.3389/fmicb.2011.00199 Improved immunological tolerance following combination therapy with CTLA-4/Ig and AAV-mediated PD-L1/2 muscle gene transfer”
BackgroundInfluentialLi, H., Tuyishime, S., Wu, T.-L., Giles-Davis, W., Zhou, D., Xiao, W., High, K. A., & Ertl, H. C. (2011) · Molecular Therapy · doi:10.1038/mt.2010.267 · Cited by 30
Self-citationAAV-mediated gene therapy for liver diseases: the prime candidate for clinical application?
van der Laan, L. J. W., Wang, Y., Tilanus, H. W., Janssen, H. L. A., & Pan, Q. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.548799 · Cited by 33
“Conceivably, these patients harbor a population of capsid-specific memory cytotoxic T cells, formed during childhood infection with the wild-type virus, probably AAV2, which were reactivated when the subject were exposed to AAV capsid via vector infusion [130].”
BackgroundAdeno-associated virus (AAV) capsid engineering in liver-directed gene therapy
Rodríguez-Márquez, E., Meumann, N., & Büning, H. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1865303 · Cited by 30
“Follow-up studies revealed a cytotoxic T lymphocyte response directed against the capsid as a cause for selective destruction of vector-transduced hepatocytes [61].”
BackgroundIn Utero Gene Therapy: Progress and Challenges
Bose, S. K., Menon, P. V., & Peranteau, W. H. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2021.05.007 · Cited by 29
“Studies in animal models and humans have demonstrated antibody and cellular responses to therapies which limit transgene expression, mediate loss of genome-edited cells, and can preclude patients from clinical trials [1,5,8,9].”
BackgroundLong, B. R., Robinson, T. M., Day, J. R., Yu, H., Lau, K., Imtiaz, U., Patton, K. S., de Hart, G., Henshaw, J., Agarwal, S., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.05.033 · Cited by 31
Wang, Y., Huang, F., Cai, H., Wu, Y., He, G., & Tan, W. (2010) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-010-0841-8 · Cited by 29
“More recently, the immune responses of the AAV capsids or transgene products in human clinical studies have been reported ( Mingozzi et al. 2007; Vandenberghe and Wilson 2007).”
BackgroundOzelo, M. C., Vidal, B., Brown, C., Notley, C. R. P., Hegadorn, C. A., Webster, S., Harpell, L., Ahlin, J., Winterborn, A., Handforth, J., et al. (2014) · Blood · doi:10.1182/blood-2013-12-545780 · Cited by 29
Dong, B., Moore, A. R., Dai, J., Roberts, S., Chu, K., Kapranov, P., Moss, B., & Xiao, W. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt404 · Cited by 29
“replication-competent AAV particle (rcAAV), is generally an undesired contaminant, which may be detrimental to the patient and can abrogate long-term transgene expression (4,5).”
Immune Responses to Muscle-Directed Adeno-Associated Viral Gene Transfer in Clinical Studies
Kumar, S. R. P., Duan, D., & Herzog, R. W. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.056 · Cited by 28
“22 Immune suppressive regimens (prophylactic or on demand), primarily based on steroid drugs, are now being employed and, to some extent, are successful in controlling/preventing the elicitation of cellular responses.”
Gene Therapies in Clinical Development to Treat Retinal Disorders
McClements, M. E., Elsayed, M. E. A. A., Major, L., de la Cámara, C. M.-F., & MacLaren, R. E. (2024) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-024-00722-0 · Cited by 31
Cabrera-Pérez, R., Vila‐Julià, F., Hirano, M., Mingozzi, F., Torres‐Torronteras, J., & Martí, R. (2019) · Human Gene Therapy · doi:10.1089/hum.2018.217 · Cited by 31
Self-citationPabinger, I., Ayash‐Rashkovsky, M., Escobar, M. A., Konkle, B. A., Mingot‐Castellano, M. E., Mullins, E. S., Négrier, C., Pan, L., Rajavel, K. S., Yan, B., et al. (2024) · Gene Therapy · doi:10.1038/s41434-024-00441-5 · Cited by 31
Raj, D., Davidoff, A. M., & Nathwani, A. C. (2011) · Expert Review of Hematology · doi:10.1586/ehm.11.48 · Cited by 27
Regenerative nanomedicine and the treatment of degenerative retinal diseases
Zarbin, M. A., Montemagno, C. D., Leary, J. F., & Ritch, R. H. (2011) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.167 · Cited by 29
Gene Therapy for the Treatment of Neurological Disorders: Metabolic Disorders
Gessler, D. J., & Gao, G. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-3271-9_30 · Cited by 29
Recombinant AAV-directed gene therapy for type I glycogen storage diseases
Chou, J. Y., & Mansfield, B. C. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.578067 · Cited by 27
“Given the difference in immune reactivity seen between small and large animal models [73-77], it is important to replicate these results in the canine GSD-Ia model.”
BackgroundTanaka, T., Hanaoka, H., & Sakurai, S. (2020) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2020.08.002 · Cited by 27
Progress and Challenges in the Treatment of Fabry Disease
Lenders, M., Menke, E. R., & Brand, E. (2025) · BioDrugs · doi:10.1007/s40259-025-00723-3 · Cited by 30
Hutt, J. A., Assaf, B. T., Bolon, B. N., Cavagnaro, J. A., Galbreath, E. J., Grubor, B., Kattenhorn, L. M., Romeike, A., & Whiteley, L. O. (2021) · Toxicologic Pathology · doi:10.1177/01926233211041962 · Cited by 28
Nienhuis, A. W., Nathwani, A. C., & Davidoff, A. M. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.018 · Cited by 27
“12,13 Systematic studies have resulted in the identification of multiple AAV serotypes.”
Library Selection and Directed Evolution Approaches to Engineering Targeted Viral Vectors
Jang, J., Lim, K., & Schaffer, D. V. (2007) · Biotechnology and Bioengineering · doi:10.1002/bit.21541 · Cited by 26
“Furthermore, even serotypes that activate distinct sets of B cells can still share T cell epitopes (Mingozzi et al., 2007), also a challenging problem to address.”
BackgroundThe deLIVERed promises of gene therapy: Past, present, and future of liver-directed gene therapy
Puzzo, F., & Kay, M. A. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.041 · Cited by 31
“148 The breakthrough in gene therapy for hemophilia B occurred during a trial in which patients exhibiting elevated liver enzyme levels were successfully treated with a short course of corticosteroids.”
Hardet, R., Chevalier, B., Dupaty, L., Naïmi, Y., Riou, G., Drouot, L., Jean, L., Salvetti, A., Boyer, O., & Adriouch, S. (2016) · Molecular Therapy · doi:10.1038/mt.2015.146 · Cited by 19
Chaanine, A. H., Nonnenmacher, M., Kohlbrenner, E., Jin, D., Kovacic, J. C., Akar, F. G., Hajjar, R. J., & Weber, T. (2014) · Gene Therapy · doi:10.1038/gt.2014.7 · Cited by 25
Keller, W. R., Picciano, A. L., Wilson, K., Xu, J., Khasa, H., & Wendeler, M. (2024) · Journal of Chromatography A · doi:10.1016/j.chroma.2024.464632 · Cited by 27
Development of AAV-Mediated Gene Therapy Approaches to Treat Skeletal Diseases
Lin, C., Greenblatt, M. B., Gao, G., & Shim, J. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.022 · Cited by 25
“49 Unlike animal models, such as rodents, dogs, sheep, and pigs showing low immunogenicity and long-term persistence of AAVs, 50 human patients treated with high dose of AAVs develop cytotoxic CD8 + T responses, 51 B cell-mediated production of neutralizing antibodies against AAV capsid, and immune…”
Gene Therapy for Hemophilia: Progress to Date
Chapin, J. C., & Monahan, P. E. (2017) · BioDrugs · doi:10.1007/s40259-017-0255-0 · Cited by 26
“Furthermore, 50% of healthy US adults circulating AAV capsid-specific CD8? and CD4? T cells, with high rates of cross-reactivity to different AAV serotypes [133–136], related to the degree of capsid amino acid sequence conservation [137].”
BackgroundBartolo, L., Li Chung Tong, S., Chappert, P., Urbain, D., Collaud, F., Colella, P., Richard, I., Ronzitti, G., Demengeot, J., Gross, D. A., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.127008 · Cited by 23
Self-citationMicroRNA-mediated immune modulation as a therapeutic strategy in host-implant integration
Ong, S., Biswas, S. K., & Wong, S. C. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.05.013 · Cited by 26
Carestia, A., Kim, S.-J., Horling, F., Rottensteiner, H., Lubich, C., Reipert, B. M., Crowe, B. A., & Jenne, C. N. (2021) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.10.023 · Cited by 24
Purdy, R., John, M., Bray, A., Clare, A. J., Copland, D. A., Chan, Y. K., Henderson, R. H., Nerinckx, F., Leroy, B. P., Yang, P., et al. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101354 · Cited by 24
“Detection of AAV components by the innate immune system also leads to the AAV-directed adaptive immune response and potential loss of transgene expression in transduced cells (Mingozzi et al., 2007; Xiang et al., 2020).”
Lüscher, C., Emiliani, V., Farahany, N. A., Gittis, A. H., Gradinaru, V., High, K. A., Roska, B., Sahel, J., Yizhar, O., Zeng, H., et al. (2025) · Nature Neuroscience · doi:10.1038/s41593-025-02097-9 · Cited by 30
Self-citationHaemophilia gene therapy: From trailblazer to gamechanger
Evens, H., Chuah, M., & VandenDriessche, T. (2018) · Haemophilia · doi:10.1111/hae.13494 · Cited by 26
Brunetti‐Pierri, N., Grove, N. C., Zuo, Y., Edwards, R., Palmer, D. J., Cerullo, V., Teruya, J., & Ng, P. (2009) · Human Gene Therapy · doi:10.1089/hum.2008.084 · Cited by 24
“…AAV vector, the fact that two subjects developed transient transaminitis suggests a direct relationship between the AAV dose and the levels of hepatotoxicity as a consequence of an adaptive cellular immune response against the transduced hepatocytes (Manno et al. , 2006; Mingozzi et al. , 2007).”
Metadata
- Authors
- Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., Pierce, G. F., Ertl, H. C. J., & High, K. A.
- Affiliations
- Children's Hospital of Philadelphia (US)
- The University of Sydney (AU)
- Hemophilia Center of Western Pennsylvania (US)
- The Wistar Institute (US)
- Corresponding author
- High, Katherine A
- ORCID
- Venue
- Nature Medicine
- Published
- 2007-03-18
- Volume
- 13
- Issue
- 4
- Pages
- 419-422
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2007261697
- Cited by
- 748
- References
- 8
- Citations by year
- 2026: 34 · 2025: 43 · 2024: 43 · 2023: 41 · 2022: 34 · 2021: 58 · 2020: 43 · 2019: 40 · 2018: 28 · 2017: 38 · 2016: 24 · 2015: 40 · 2014: 41 · 2013: 37 · 2012: 40
- FWCI
- 22.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (1f32hl069647-01)
- National Heart, Lung, and Blood Institute (F32 HL69647, P01HL078810, T32HL007439)
- National Institute of Allergy and Infectious Diseases (P30AI045008)
- National Institute of Diabetes and Digestive and Kidney Diseases (T32DK007748)
- National Center for Research Resources (M01RR000056, M01RR000240)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- adeno-associated virus, AAV capsid, CD8+ T cells, AAV serotype 2, gene transfer, T cell memory, T cell proliferation
- MeSH terms
- Dependovirus, Animals, Capsid, Humans, Lymphocyte Activation, Parvoviridae Infections, Peptides, Gene Transfer Techniques, CD8-Positive T-Lymphocytes, Hepatocytes, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.